Table of Contents
Bosentan PK in PAH Patients Concentrations after 62.5 mg Single Dose
Interaction with Ketoconazole Bosentan Trough Plasma Levels
Choice of Doses for Clinical Trials
Long-term Exposure to Bosentan
Change in WBC and Platelets 8 Placebo-controlled Studies
Risk of Hospitalization AC-052-352
Patient Registry (To Be Discussed with the FDA)
|
Author: Chris and Marty
|